GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA)
-
Published:2024-09-10
Issue:
Volume:
Page:
-
ISSN:0340-5354
-
Container-title:Journal of Neurology
-
language:en
-
Short-container-title:J Neurol
Author:
Katzdobler Sabrina, Nübling Georg, Klietz Martin, Fietzek Urban M., Palleis Carla, Bernhardt Alexander M., Wegner Florian, Huber Meret, Rogozinski Sophia, Schneider Luisa-Sophie, Spruth Eike Jakob, Beyle Aline, Vogt Ina R., Brandt Moritz, Hansen Niels, Glanz Wenzel, Brockmann Kathrin, Spottke Annika, Hoffmann Daniel C., Peters Oliver, Priller Josef, Wiltfang Jens, Düzel Emrah, Schneider Anja, Falkenburger Björn, Klockgether Thomas, Gasser Thomas, Nuscher Brigitte, Haass Christian, Höglinger Günter, Levin JohannesORCID
Abstract
Abstract
Background
Multiple system atrophy (MSA), an atypical parkinsonian syndrome, is a rapidly progressive neurodegenerative disease with currently no established fluid biomarkers available. MSA is characterized by an oligodendroglial α-synucleinopathy, progressive neuronal cell loss and concomitant astrocytosis. Here, we investigate glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) as fluid biomarkers for differential diagnosis, assessment of clinical disease severity and prediction of disease progression in MSA.
Methods
GFAP and NfL levels were analyzed in plasma and CSF samples of 47 MSA patients as well as 24 Parkinson’s disease (PD) and 25 healthy controls (HC) as reference cohorts. In MSA, biomarker levels were correlated to baseline and longitudinal clinical disease severity (UMSARS scores).
Results
In MSA, GFAP levels in CSF and plasma predicted baseline clinical disease severity as indicated by UMSARS scores, while NfL levels predicted clinical disease progression as indicated by longitudinal changes in UMSARS scores. Cross-sectionally, NfL levels in CSF and plasma were significantly elevated in MSA compared to both PD and HC. Receiver operating curves (ROC) indicated high diagnostic accuracy of NfL for distinguishing MSA from PD (CSF: AUC = 0.97, 95% CI 0.90–1.00; plasma: AUC = 0.90, 95% CI 0.81–1.00).
Discussion
In MSA, GFAP shows promise as novel biomarker for assessing current clinical disease severity, while NfL might serve as biomarker for prediction of disease progression and differential diagnosis of MSA against PD.
Funder
Deutsche Forschungsgemeinschaft Anton and Petra Ehrmann-Stiftung Lüneburg Foundation Klinikum der Universität München
Publisher
Springer Science and Business Media LLC
Reference42 articles.
1. Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, Hardy J, Leverenz JB, Tredici KD, Wszolek ZK, Litvan I (2009) Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria. Lancet Neurol 8(12):1150–1157 2. Trojanowski JQ, Revesz T (2007) Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropath Appl Neuro 33(6):615–620 3. Mavroeidi P, Xilouri M (2021) Neurons and glia interplay in α-synucleinopathies. Int J Mol Sci 22(9):4994 4. Wang P, Ye Y (2021) Astrocytes in neurodegenerative diseases: a perspective from tauopathy and α-synucleinopathy. Life 11(9):938 5. Fanciulli A, Stankovic I, Krismer F, Seppi K, Levin J, Wenning GK (2019) Multiple system atrophy. Int Rev Neurobiol 149:137–192
|
|